APOA1 and cancer: Kim J et al. [81] developed engineered eHNPs composed of apolipoprotein A1 and CD15 (a murine SHH MB cancer stem-like cell target) to selectively deliver the Smo inhibitor, sonidegib (LDE-225) in the SHH MB tumor site.